Daniel A. Pollyea, MD, on the Impact of Venetoclax in IDH-Mutant AML
The leukemia expert discussed the clinical implications of findings demonstrating improved response for patients with acute myeloid leukemia with IDH mutations.
In an interview with CancerNetwork®, Daniel A. Pollyea, MD, of the University of Colorado Cancer Center, discusses the clinical implications of a pooled analysis examining treatment with venetoclax (Venclexta) and azacitidine (Vidiza) versus azacitidine alone for patients with acute myeloid leukemia with IDH mutations.
Transcription:
The clinical observation that we’re making here [is that this trial] opens the door very clearly for folks in the community to figure out, “why is it that venetoclax and IDH [mutations] go so well together? And if we can figure that out, is it possible then to tweak the IDH wild-type [tumors] and recapitulate the results that we see in [this setting] so that in the future, all patients, regardless of IDH status, could have this type of response to venetoclax, maybe by adding another drug into the mix or something along those lines.
